Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

This might drive the stock higher in the near term. Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H... Shares of Hikma ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

Ionis Pharmaceuticals exceeded revenue estimates by 3.4%, reporting $134 million against a $129.57 million expectation. Spinraza royalties decreased by $10 million year over year to $57 million ...

Revenue from its biologics segment was $461 million, missing expectations of $470.57 million. Its pharmaceuticals and consumer health segment posted sales of $563 million, below estimates of $566. ...

The growth in the adolescent and young adult market for Rylaze is slower than anticipated, impacting overall revenue expectations. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) lowered its oncology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...